Literature DB >> 12473517

Epigenetics in cancer: implications for early detection and prevention.

Mukesh Verma1, Sudhir Srivastava.   

Abstract

Knowledge of the molecular events that occur during the early stages of cancer has advanced rapidly. The initiation and development of cancer involves several molecular changes, which include epigenetic alterations. Epigenetics is the study of modifications in gene expression that do not involve changes in DNA nucleotide sequences. Modifications in gene expression through methylation of DNA and remodelling of chromatin via histone proteins are believed to be the most important of the epigenetic changes. The study of epigenetics offers great potential for the identification of biomarkers that can be used to detect and diagnose cancer in its earliest stages and to accurately assess individual risk. There has been a recent surge of interest among researchers as variations in the methylation of DNA have been shown to be the most consistent molecular changes in many neoplasms. An important distinction between a genetic and an epigenetic change in cancer is that epigenetic changes can be reversed more easily by use of therapeutic interventions. The discovery of these basic premises should stimulate much future research on epigenetics.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12473517     DOI: 10.1016/s1470-2045(02)00932-4

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  32 in total

1.  Perspectives on personalized cancer care.

Authors:  Garrett M Dancika; Dan Theodorescu
Journal:  Urol Oncol       Date:  2012 Mar-Apr       Impact factor: 3.498

Review 2.  Targeting the epigenome with bioactive food components for cancer prevention.

Authors:  Thomas Prates Ong; Fernando Salvador Moreno; Sharon Ann Ross
Journal:  J Nutrigenet Nutrigenomics       Date:  2012-02-22

3.  Base-resolution methylation patterns accurately predict transcription factor bindings in vivo.

Authors:  Tianlei Xu; Ben Li; Meng Zhao; Keith E Szulwach; R Craig Street; Li Lin; Bing Yao; Feiran Zhang; Peng Jin; Hao Wu; Zhaohui S Qin
Journal:  Nucleic Acids Res       Date:  2015-02-26       Impact factor: 16.971

Review 4.  Molecular screening of cancer: the future is here.

Authors:  Sudhir Srivastava
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

5.  High frequency of BRCA1/2 and p53 somatic inactivation in sporadic ovarian cancer.

Authors:  Michal Zikan; Marketa Janatova; David Pavlista; Petr Pohlreich
Journal:  J Genet       Date:  2007-08       Impact factor: 1.166

6.  Epigenetic inactivation of galanin receptor 1 in head and neck cancer.

Authors:  Kiyoshi Misawa; Yo Ueda; Takeharu Kanazawa; Yuki Misawa; Ilwhan Jang; John Chadwick Brenner; Tetsuya Ogawa; Satoru Takebayashi; Reidar A Grenman; James G Herman; Hiroyuki Mineta; Thomas E Carey
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

Review 7.  Epigenetic research in cancer epidemiology: trends, opportunities, and challenges.

Authors:  Mukesh Verma; Scott Rogers; Rao L Divi; Sheri D Schully; Stefanie Nelson; L Joseph Su; Sharon A Ross; Susan Pilch; Deborah M Winn; Muin J Khoury
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-12-10       Impact factor: 4.254

8.  miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells.

Authors:  Nicola Amodio; Dina Bellizzi; Marzia Leotta; Lavinia Raimondi; Lavinia Biamonte; Patrizia D'Aquila; Maria Teresa Di Martino; Teresa Calimeri; Marco Rossi; Marta Lionetti; Emanuela Leone; Giuseppe Passarino; Antonino Neri; Antonio Giordano; Pierosandro Tagliaferri; Pierfrancesco Tassone
Journal:  Cell Cycle       Date:  2013-09-25       Impact factor: 4.534

Review 9.  Opportunities and challenges for selected emerging technologies in cancer epidemiology: mitochondrial, epigenomic, metabolomic, and telomerase profiling.

Authors:  Mukesh Verma; Muin J Khoury; John P A Ioannidis
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-12-14       Impact factor: 4.254

10.  The combination effect of sodium butyrate and 5-Aza-2'-deoxycytidine on radiosensitivity in RKO colorectal cancer and MCF-7 breast cancer cell lines.

Authors:  Hang Joo Cho; Sin Young Kim; Kee Hwan Kim; Won Kyung Kang; Ji Il Kim; Seong Tack Oh; Jeong Soo Kim; Chang Hyeok An
Journal:  World J Surg Oncol       Date:  2009-05-21       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.